In addition to its observed benefit in patients with subtle NK cell dysfunction, IFN-α-2b demonstrated marked clinical efficacy in a patient with Dedicator of Cytokinesis 8 (DOCK8) deficiency, a primary immunodeficiency associated with severe, recalcitrant cutaneous warts. This evidence concerns the gene DOCK8 and inborn error of immunity.